Pharming announces US FDA approval of Joenja® (leniolisib) as the first and only treatment indicated for APDS

The FDA evaluated the Joenja® application for APDS under Priority Review, which is granted to therapies that have the potential to provide significant improvements in the treatment, diagnosis or prevention of serious conditions. Joenja® is expected to launch in the US in early April and will be available for shipment in mid-April. Pharming held a conference call for investors and analysts on March 27, 2023 at 14:00 CEST/08:00 EST. Download the presentation slides and transcript below and . Resources For further information, please contact: Media Relations Investor Relations Quick links

The release as fetched from its publisher. pharming.com ↗